Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) Stock Overview
Explore Dianthus Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
3.2B
P/E Ratio
0.00
EPS (TTM)
$-4.20
ROE
0.00%
DNTH Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Dianthus Therapeutics, Inc. (DNTH) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 69.20, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $43.22.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.00 and a market capitalization of 3.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.